Call for Proposals ($50k): Tisch Cancer Institute & Drug Discovery Institute

Dear TCI Community,

The Tisch Cancer Institute (TCI) is partnering with the [Drug Development Institute (DDI)](#) to create a 'Call for Proposals' to translate your work towards a therapeutic small molecule or monoclonal antibody. The goal of the TCI/DDI partnership is to identify laboratory work that may be ready for the first steps in therapeutic discovery but would benefit from drug development "know-how" and seed money.

Perhaps you have an interesting target or a new and useful translational cancer model that can serve as a discovery platform. Please apply if you feel your work has the potential to yield therapeutic hits and you are committed to using the preliminary data to follow through on developing a lead therapeutic.

We will supply guidance on assay validation and screening (e.g. compound libraries), and also medicinal chemistry/ antibody project advice.

To apply for up to **$50K** in seed funding including DDI resources, please **write a one page overview** of your goals for translating your work.

Successful applications will answer the following questions:

- *What is the cancer you are addressing?*
- *What is the target? Do you have functional data validating the target?*
- *Do you have a "screenable" platform (how is your assay currently performed)?*
- *What current or emerging therapies already exist and how would yours be different?*
- *Relevant publications (max. 5)*

Submissions will be reviewed by an expert committee. The selected proposal will be structured into a milestone driven plan and budget in collaboration with the Review Committee. The project duration should target 6-12 months.

We will accept applications through October 31, 2018.
Please submit to ross.cagan@mssm.edu and louise.lammers@mssm.edu.

Sincerely,

Ross Cagan   Louise Lammers
Co-Leader,   Co-Director,
Cancer Clinical Investigation   Drug Discovery Institute
Program of the TCI